CNTO-6785

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameCNTO-6785
Drug Alias NameCNTO-6785FTC-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPsoriasisPulmonary Disease, Chronic ObstructiveArthritis, Rheumatoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumTaiwan +[14] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMorphosys AgJohnson & Johnson Innovative Medicine
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShandong Fangtansi Biopharmaceutical Co LtdShandong Fontacea Pharmaceutical Institute Co Ltd
Inactive CompaniesJanssen-Cilag International NvJanssen Research & Development Llc
Active IndicationsPsoriasisSpondylitis, AnkylosingArthritis, Psoriatic
Inactive IndicationsPulmonary Disease, Chronic ObstructiveArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A